Back to News
Mar 9, 2026 8:01 AM

Hims & Hers, Novo Nordisk Weight-Loss Drug Deal Ends Legal Feud, Stock Soars

Hims & Hers Health Inc. (NYSE:HIMS) shares are up during Monday's premarket session as the company has reportedly ended its legal feud with Novo Nordisk A/S (NYSE:NVO), paving the way for a new partnership involving weight-loss drugs.

Novo Nordisk Partners with Hims & Hers

Novo Nordisk has decided to sell its weight-loss drug through Hims & Hers' telehealth platform, following a lawsuit over patent violations regarding a compounded version of semaglutide products.

In February, Hims & Hers Health agreed to acquire Eucalyptus, a digital health leader, which is expected to enhance Hims & Hers' international presence.

Hims and Hers 2026 Guidance Below Expectations

Hims & Hers Health reported fourth-quarter revenue of $617.82 million, falling short of analyst estimates of $619.22 million.

However, the company did beat earnings expectations with a reported 8 cents per share, surpassing estimates of 3 cents per share.

Hims & Hers also provided guidance for first-quarter revenue between $600 million and $625 million, which is below the analyst ...